Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Cancer Clinical Trial

— SUP-R  

Official title:

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02555748
• Other study ID #: 14 URO 06
• Status: Completed
• Phase: Phase 4
• Start date: November 17, 2015
• Est. completion date: January 16, 2020

Study information

• Verified date: January 2021
• Source: Institut Claudius Regaud
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib). The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: January 16, 2020
• Est. primary completion date: January 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma.

2. Measurable tumours as defined by RECIST criteria version 1.1.

3. Age = 18 years old.

4. WHO Performance Status = 2.

5. Life expectancy = 6 months.

6. Adequate cardiac function (baseline Left Ventricular Ejection Fraction (LVEF) = 50% determined by Multiple Gated Acquisition scan (MUGA) or echocardiography) and pulmonary function.

7. Renal function defined as creatinine clearance (Cockcroft and Gault formula) > 30 mL/min.

8. Adequate liver function defined as: total bilirubin = 1.5 x Upper Limit of Normal (ULN); Alanine AminoTansferase (ALAT) and Aspartate AminoTransferase (ASAT) = 2.5 x ULN; Concomitant elevation in bilirubin and ASAT/ALAT above 1.0 x ULN is not allowed.

9. Patients must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up.

10. Negative pregnancy test for women in childbearing potential.

11. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study (before study entry and until 30 days after the last administration of study treatment).

12. Patients affiliated to a social health insurance.

Exclusion Criteria:

1. Patients without any venous access for blood sampling.

2. Hypersensitivity to the active substance or to any of the excipients.

3. History or clinical evidence of central nervous system (CNS) metastases, except for individuals who have previously-treated CNS metastases.

4. Corrected QT interval (QTc) > 480msecs using Bazett's formula.

5. Patients with other concurrent severe and/or uncontrolled medical disease which could

compromise participation in the study, such as, but not limited to:

• Uncontrolled infection.
• Cardiovascular conditions within the last 6 months such as cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New-York Heart Association (NYHA), clinically significant irregular heartbeat requiring medication.
• Poorly controlled hypertension [defined as systolic blood pressure of =140 mmHg or diastolic pressure of =90 mmHg).
• History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months. Note: patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.

6. Evidence of active bleeding or bleeding diathesis.

7. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cytochrome P450 isoenzyme 3A4 (CYP3A4) within the last 14 days prior to inclusion and/or during the study.

8. Patients already treated with an anticancer treatment in the previous four weeks or patient requiring anticancer treatment during the study (chemotherapy, immunotherapy, hormonotherapy, radiotherapy or surgery).

9. Pregnant or breast-feeding women.

10. Positive diagnostic of HIV, B and C hepatitis.

11. Patients with serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety, provision of informed consent, or compliance to study procedures.

12. Patients who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Metastatic Renal Cell Cancer

Intervention

Drug:
• Pazopanib

• Sunitinib

Locations

Country	Name	City	State
France	CHU DE BORDEAUX - Hôpital Saint-André	Bordeaux
France	Institut Bergonie	Bordeaux
France	CHU DE LIMOGES - Hôpital Dupuytren	Limoges
France	Centre Leon Berard	Lyon
France	Institut Paoli Calmettes	Marseille
France	Institut Regional Du Cancer Montpellier	Montpellier
France	CH RODEZ	Rodez
France	Institut Claudius Regaud	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
Institut Claudius Regaud	University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part I: Pharmacokinetics - Pazopanib or Sunitinib plasma concentrations		On day 1 and day 15 during cycle 1 and cycle 2 (cycle length is 6 weeks)
Primary	Part II: Tolerance - Proportion of patients without treatment discontinuation due to adverse event (AE) during the first year.	This corresponds to the number of patients without treatment discontinuation due to AE among the total number of patients in each group.	5.5 years
Primary	Part II: Efficacy - Proportion of patients without progression at 1 year. This corresponds to the number of patients without progression at 1 year among the total number of patients in each group		5.5 years
Primary	Part I: Adverse Events according to NCI toxicity scale (version 4.03)		1.5 years
Secondary	Part I and II: Objective Response (e.g. Complete or Partial Response)	Objective Response will be defined using RECIST Criteria version 1.1.	5.5 years
Secondary	Part I and II:- Progression free survival.	Progression free survival is defined as the time from inclusion until progression (RECIST Criteria version 1.1) or death. Patients alive at last follow-up news are censored at this date.	5.5 years
Secondary	Part I and II: Safety according to the classification of the NCI: Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03.		5.5 years
Secondary	Part I and II: Hand-foot syndrome (HFS)	Hand-foot syndrome (HFS) will be evaluated using the HFS-14 questionnaire. This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment.	5.5 years
Secondary	Part I and II: Quality of life using the quality of life questionnaire (QLQ)-C30	Quality of life will be evaluated using the QLQ-C30 questionnaire	5.5 years